Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003

N W Clarke; A Ali; F C Ingleby; A Hoyle; C L Amos; G Attard; C D Brawley; J Calvert; S Chowdhury; A Cook; W Cross; D P Dearnaley; H Douis; D Gilbert; S Gillessen; R J Jones; R E Langley; A MacNair; Z Malik; M D Mason; D Matheson; R Millman; C C Parker; A W S Ritchie; H Rush; J M Russell; J Brown; S Beesley; A Birtle; L Capaldi; J Gale; S Gibbs; A Lydon; A Nikapota; A Omlin; J M O'Sullivan; O Parikh; A Protheroe; S Rudman; N N Srihari; M Simms; J S Tanguay; S Tolan; J Wagstaff; J Wallace; J Wylie; A Zarkar; M R Sydes; M K B Parmar; N D James; STAMPEDE investigators

doi:10.1016/j.annonc.2020.01.002

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003

Ann Oncol. 2020 Mar;31(3):442. doi: 10.1016/j.annonc.2020.01.002. Epub 2020 Jan 31.

Authors

N W Clarke¹, A Ali², F C Ingleby³, A Hoyle⁴, C L Amos⁵, G Attard⁶, C D Brawley⁵, J Calvert⁵, S Chowdhury⁷, A Cook⁵, W Cross⁸, D P Dearnaley⁹, H Douis¹⁰, D Gilbert⁵, S Gillessen¹¹, R J Jones¹², R E Langley⁵, A MacNair⁵, Z Malik¹³, M D Mason¹⁴, D Matheson¹⁵, R Millman⁵, C C Parker¹⁶, A W S Ritchie⁵, H Rush⁵, J M Russell¹⁷, J Brown¹⁸, S Beesley¹⁹, A Birtle²⁰, L Capaldi²¹, J Gale²², S Gibbs²³, A Lydon²⁴, A Nikapota²⁵, A Omlin²⁶, J M O'Sullivan²⁷, O Parikh²⁸, A Protheroe²⁹, S Rudman⁷, N N Srihari³⁰, M Simms³¹, J S Tanguay³², S Tolan¹³, J Wagstaff³³, J Wallace¹², J Wylie³⁴, A Zarkar³⁵, M R Sydes⁵, M K B Parmar⁵, N D James³⁶; STAMPEDE investigators

Affiliations

¹ Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester. Electronic address: [email protected].
² Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester.
³ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London; London School of Hygiene and Tropical Medicine, London.
⁴ Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester.
⁵ MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.
⁶ UCL Cancer Institute, London.
⁷ Guy's and Saint Thomas' NHS Foundation Trust, London.
⁸ St James University Hospital, Leeds.
⁹ Institute of Cancer Research, Sutton-London.
¹⁰ Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham.
¹¹ Division of Cancer Sciences, The University of Manchester, Manchester.
¹² Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow.
¹³ The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool.
¹⁴ Cardiff University, Cardiff.
¹⁵ Faculty of Education Health and Wellbeing, University of Wolverhampton, Wolverhampton.
¹⁶ Institute of Cancer Research, Sutton-London; RoyalMarsden NHS Foundation Trust, London.
¹⁷ Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre, Glasgow.
¹⁸ University of Sheffield, Sheffield.
¹⁹ Kent Oncology Centre, Maidstone.
²⁰ Lancashire Teaching Hospitals NHS Foundation Trust, Preston.
²¹ Worcestershire Acute Hospitals NHS Trust, Worcester.
²² Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth.
²³ Queen's Hospital, Romford.
²⁴ Torbay and South Devon NHS Foundation Trust, Torbay.
²⁵ Sussex Cancer Centre, Brighton.
²⁶ Department of Oncology and Haematology, Kantonsspital, St Gallen, Switzerland.
²⁷ Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.
²⁸ East Lancashire Hospitals NHS Trust, Blackburn, UK.
²⁹ Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
³⁰ Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.
³¹ Hull and East Yorkshire Hospitals NHS Trust, Hull, UK.
³² Velindre Cancer Centre, Cardiff, UK.
³³ Swansea University College of Medicine, Swansea, UK.
³⁴ The Christie NHS Foundation Trust, Manchester, UK.
³⁵ Heartlands Hospital, Birmingham, UK.
³⁶ Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

No abstract available

Publication types

Published Erratum

Grants and funding

3804/CRUK_/Cancer Research UK/United Kingdom